Illumina CEO deSouza: Innovation Is ‘Our North Star’
Sequencing group sees a growing role for genomics in infectious disease
The total addressable market for genomics-based infectious disease testing has expanded in recent months, says Illumina, after becoming the first company to receive a US EUA for a next-generation sequencing-based COVID-19 test. It came amid a raft of innovation activity and tuck-in M&A for the San Diego company.
